In this abstract, the authors utilize patient-reported outcomes to assess if quality of life can be a biomarker for survival in patients with renal cell carcinoma.To do so, they use the Medicare Health Outcomes Survey linked to SEER data from 1998-2014 (17 years).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
• It is never stated when the surveys were completed in relation to treatment.
The primary outcome was association with all-cause mortality (ACM). However, they also completed a competing risks models adjusted for stage, demographics, and comorbidities to evaluate RCC-specific and non-RCC-specific mortality.
They identified 1,494 patients with a median age of 73.4 years (IQR 68.8-79.3); median follow-up was 5.6 years (IQR 4.0-8.3). There were 747 deaths (all-cause) and 139 RCC-related deaths.
71% of the entire cohort was cT1 and only 15% were cT3-4. 3.4% were metastatic RCC.
While the four subgroups were somewhat balanced, there were clear discrepencies:
- Group 3 had a higher proportion of cT1 than the other 3, and less cT3-4
- Each successive group (1->4) had higher rates of metastatic disease
- Each successive group (1->4) had higher rates of cardiovascular risk factors
- Each successive group (1->4) had lower rates of male patients
On multivariable analysis, each additional MCS and PCS point reduced the hazard of ACM by 1.3% (95% CI 0.981-0.993, P< 0.001) and 2.2% (95% CI 0.972-0.985, P< 0.001), respectively. Therefore, patients that had better mental and physical QOL had reduced ACS.
In the competing risks model, the hazard ratio (HR) of RCC mortality in Groups 2, 3, and 4 were 2.71 (95% CI 1.18-6.22, P= 0.02), 4.55 (95% CI 1.57-13.18, P= 0.005), and 3.11 (95% CI 1.35-7.16, P= 0.008), respectively, compared to Group 1. The HR for non-RCC mortality were 1.50 (95% CI 1.16-1.94, P= 0.002), 1.03 (95% CI 0.59-1.78, P= 0.9), and 1.83 (95% CI 1.41-2.38, P< 0.001), respectively, relative to Group 1.
It would appear, based on this analysis, that patients with worse physical and mental self-reported QOL metrics is associated with worse ACM in RCC patients with good accuracy; lower PCS and MCS scores led to higher rates of ACM, even after accounting for differences in disease, demographics, and comorbidity. This carried forward to RCC specific mortality. In non-RCC mortality, however, low physical health was more associated with worse outcomes than poor mental health.
However, this is obviously limited by the fact that this patient-reported. More importantly, the groups were soor poorly balanced, the difference likely represent differences in metastatic disease rates, cardiovascular disease, and clinical stage.
Speaker: Ridwan Alam
Co-Authors: Hiten Patel, Phillip M. Pierorazio
Institution(s): James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University, Baltimore, MD
Written by: Thenappan Chandrasekar, MD, Clinical Fellow, University of Toronto, Twitter: @tchandra_uromd at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA